The Non-Malignant Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2019 | SAA treatment and QoL
Anita Hill, MBChB (Hons), MRCP, FRCPath, PhD, Leeds Teaching Hospital NHS Trust, Leeds, UK, discusses optimizing treatment outcomes in severe aplastic anemia and immune thrombocytopenic purpura with thrombopoietin-receptor agonists (TPO-RAs), focussing on patient quality of life (QoL). Dr Hill goes on to discuss the use of patient-oriented surveys to asses QoL. This interview took place at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.
